PF-Atlas › Mechanisms › ANZCTR

ANZCTR in IPF

Mechanism of action · idiopathic pulmonary fibrosis

Overview

ANZCTR is a therapeutic target in idiopathic pulmonary fibrosis. PF-Atlas tracks 8 drugs and 9 clinical trials acting through this mechanism.

Drugs targeting ANZCTR

Ifenprodil Inhaled mannitol PTI-808 BI 1819479 AP01 CMS AZLI 75 mg three times a day Mosliciguat

Clinical trials

Ifenprodil — NCT04318704 Inhaled mannitol — NCT00669331 PTI-808 — NCT03251092 BI 1819479 — NCT06335303 AP01 — NCT06951217 CMS — NCT03093974 AZLI 75 mg three times a day — NCT00112359 Inhaled mannitol — NCT02134353 Mosliciguat — NCT06635850

Medical disclaimer. This is a research summary, not medical advice.